Capso Vision
Founded Year
2006Stage
Debt - II | AliveTotal Raised
$69.16MLast Raised
$980K | 3 yrs agoAbout Capso Vision
CapsoVision develops GI medical devices that empower physicians and patients with devices that meet high standards for safety, reliability and patient care. Capso Vision was founded in 2006 and is based in Saratoga, California.
Missing:Capso Vision'sProduct Demo & Case Studies
Promote your product offering to tech buyers.
達到1000年代的買家使用CB見解來鑒別188bet游戏ify vendors, demo products, and make purchasing decisions.
Missing:Capso Vision'sProduct & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Capso Vision
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Capso Vision is included in3 Expert Collections,includingMedical Devices.
Medical Devices
11,721 items
Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.
Digital Health
12,349 items
Technologies, platforms, and systems that engage consumers for lifestyle, wellness, or health-related purposes; capture, store, or transmit health data; and/or support life science and clinical operations. (DiME, DTA, HealthXL, & NODE.Health)
Health IT
7,901 items
Capso VisionPatents
Capso Vision has filed 106 patents.
The 3 most popular patent topics include:
- Endoscopy
- Image processing
- 3D imaging
Application Date |
Grant Date |
Title |
Related Topics |
Status |
|---|---|---|---|---|
|
7/22/2021 |
3/28/2023 |
Endoscopy, Medical equipment, Electrical signal connectors, Gastroenterology, Esophagus disorders |
Grant |
Application Date |
7/22/2021 |
|---|---|
Grant Date |
3/28/2023 |
Title |
|
Related Topics |
Endoscopy, Medical equipment, Electrical signal connectors, Gastroenterology, Esophagus disorders |
Status |
Grant |
LatestCapso VisionNews
Sep 20, 2022
北美智能藥丸市場預計to reach US$ 5,300.85 million by 2028 from US$ 2,314.71 million in 2021. The market is estimated to grow at a CAGR of 12.6% from 2021 to 2028. The geriatric population is highly vulnerable to gastrointestinal disorders. Various smart pills are now being analyzed for potential application in therapeutics and diagnosing several acute and chronic diseases. Patients with chronic diseases who follow a specified dose of medication at the target site are anticipated to form a large customer base for advanced drug delivery products. The increasing demand for minimally invasive surgical procedures has led to innovative techniques such as capsule endoscopy. Capsule endoscopy is expected to replace traditional endoscopy methods due to its advantages, including ease of administration and detailed observation of the gastrointestinal tract. The capsule endoscopy plays a vital role in the early diagnosis and proper treatment of these disorders, along with hybrid imaging technologies and new component innovations. For instance, as per the University of Texas Health Science Center, the deployment of various colorectal cancer screening procedures, such as capsule endoscopy, improves adherence to screening. The university conducted a study comprising randomly assigned patients aged 50 to 75 and inferred that capsule endoscopy gives better diagnostic results than CT colonography. Such findings are estimated to boost the segment growth over the forecast period. Patients with a maximal requirement for home healthcare services face challenges concerning access and use of smart pills. This has resulted in developers and producers increasing the accessibility and usability of these devices, thereby facilitating the interpretation of data more simply. Most industries offer compatible software for collecting data over a longer duration, conveying valuable information about patient health, and providing suggestions for enhancing their quality of life. Being connected to smartphones through Bluetooth and providing data in user-friendly & statistical format is boosting the demand for smart pills. With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the smart pills market. The North America smart pills market is expected to grow at a good CAGR during the forecast period. Market Dynamics Future Trends North America Smart Pills Market Segmentation The North America smart pills market is segmented based on application, disease indication, and end user. Based on application, the market is segmented into capsule endoscopy, drug delivery, and patient monitoring. The capsule endoscopy segment is sub segmented into small bowel video capsule endoscopy, colon capsule endoscopy, controllable capsule endoscopy, storable capsule endoscopy, and other capsule endoscopy. Based on disease indication, the market is segmented into gastrointestinal diseases, neurological disorders, cancer, inherited disorders, and other disease indications. Based on end user, the market is segmented into hospitals and clinics, research institutes, and home healthcare. Key Topics Covered:
Capso VisionFrequently Asked Questions (FAQ)
When was Capso Vision founded?
Capso Vision was founded in 2006.
Where is Capso Vision's headquarters?
Capso Vision's headquarters is located at 18805 Cox Avenue, Saratoga.
What is Capso Vision's latest funding round?
Capso Vision's latest funding round is Debt - II.
How much did Capso Vision raise?
Capso Vision raised a total of $69.16M.
Who are the investors of Capso Vision?
Investors of Capso Vision include Paycheck Protection Program.
Who are Capso Vision's competitors?
Competitors of Capso Vision include SynergEyes, Visioneering Technologies, TrueVision Systems, WaveTec Vision, Ophthonix and 13 more.
Compare Capso Vision to Competitors
Kjaya is a company that received a SBIR Phase I grant for a project entitled: Semi-Autonomous Adaptive Neural and Genetic Segmentation of Medical Images. Their Phase I project will implement a physician-assisted, real-time adaptive system for the segmentation of anatomical structures in 3D medical image data. Medical image segmentation seeks to change the representation of an anatomical structure, making it more easily analyzed. Because of the extreme variability of these structures in biological systems, current idiosyncratic manual methods currently in use are tedious, time consuming, and error prone. Image segmentation cannot in general be programmatically solved. The proposed system is a Neural Network (NN) based adaptation of the individual data using parallel Graphics Processing Units (GPUs) and coupled with a Genetic Algorithm (GA) based adaptation across GPU cores. The system will build a diagnostically useful segmentation of the anatomical feature within seconds from an area of interest outlined by a physician using a Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) scan. Fast growth in medical imaging overwhelms available diagnosticians. An intuitive and inexpensive system to quickly and accurately deliver diagnostic relevant segmentation of medical images offers tremendous commercial value. Currently, each scan requires approximately 50 minutes of manual preparation. The diagnosis and treatment of an estimated 20 percent of diseases benefit from medical imaging. Newer scanning technologies have increased in resolution, but such techniques have not made segmenting easier or faster. The proposed method will enable more diagnostics to be done with the quality controlled directly by physicians.
TrueVision Systems, dba TrueVisions 3D Surgical, provides digital 3D visualization and guidance for microsurgery. The company has developed an intelligent, real-time, 3D surgical visualization and computer-aided guidance platform. TrueVision combines 3D visualization and guidance software applications focused on improving accuracy, efficiency, and outcomes for both surgeons and patients. The company is developing 3D guidance applications for microsurgery to improve surgical efficiencies and patient outcomes. The Refractive Cataract Toolset is a computer-aided software for astigmatic correction and advanced IOL positioning.
CardioOptics is a developer of Trans-Blood Vision products to provide catheter-based direct visualization through blood using infrared light.
Gamma Medica Ideas, Inc. engages in designing, building, selling, and servicing pre-clinical and clinical imaging systems.
Holochip manufactures adaptive polymer singlet lenses that allow adjustability of focal length without changing the location of the lens. This flexibility aims to provide a compact, rugged and reliable solution for utilizing and manipulating light.
Prosurgics develops the FreeHand Surgeon, a robotic camera holder
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.